alexa Strontium Beta-Irradiation: Can it Prove Strong Enough in Curbing the Ophthalmic Hydra Called Pterygium | OMICS International
ISSN: 2161-1076
Surgery: Current Research
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Strontium Beta-Irradiation: Can it Prove Strong Enough in Curbing the Ophthalmic Hydra Called Pterygium

Abhishek Onkar1*, Saurabh Samdariya2, Puneet Pareek2 and Suwarna Suman1

1Department of Ophthalmology, AIIMS Jodhpur, India

2Department of Radiation Oncology, AIIMS Jodhpur, India

*Corresponding Author:
Dr. Abhishek Onkar
402 Belita, Arihant Adita
Gangana Pal Road, Near Lady Pillar Convent School
Jodhpur, Rajasthan-342014, India
Tel: 91-9871984534
E-mail: [email protected]

Received Date: June 07, 2017; Accepted Date: June 26, 2017; Published Date: July 02, 2017

Citation: Onkar A, Samdariya S, Pareek P, Suman S (2017) Strontium Beta- Irradiation: Can it Prove Strong Enough in Curbing the Ophthalmic Hydra Called Pterygium. Surgery Curr Res 7: 298. doi: 10.4172/2161-1076.1000298

Copyright: © 2017 Onkar A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Surgery: Current Research

Abstract

No other ophthalmic disorder, or may be any medical disorder, has elicited so much interest as pterygium. Even though eons have passed since it was first discovered, its propensity for regrowth like tentacles of hydra, continue to perplex the ophthalmic community. Its propensity for recurrences has attracted all and the sundry and newer modalities are being propounded to prevent recurrences. This article reviews the role of radiation therapy for recurrence prevention in pterygium management.

Keywords

Strontium beta-irradiation; Ophthalmic; Pterygium; Radiation therapy

Introduction

Etymologically derived from the Greek word ‘pterygion’ meaning small wing, pterygium has been in vogue since the times of Sushruta (6th century B.C.). It is a triangular, wing-like fibro-vascular encroachment of degenerative sub-epithelial conjunctiva, straddling the limbus, onto the cornea (Figure 1). Pterygium, with a prevalence of 0.3 to 29%, is common in the ‘pterygium belt’ lying 37º on either side of equator [1,2]. Chronic exposure to ultra-violet B radiations, limbal stem cell deficiency, human papilloma virus infection, p53 gene mutations and imbalance of matrix metalloproteinases (MMP) and tissue inhibitors of metalloproteinases (TIMP) have been strongly implicated in pterygium causation [3]. Whereas diagnosis and management of primary pterygium is an iotic task, managing recurrences is a titanic one.

surgery-current-research-male

Figure 1: Pterygium in a 17 year old male.

Discussion

While primary pterygium excision with conjunctival graft remains the standard procedure for prevention of recurrences with recurrence rate of 2-35%, many other methodologies have been used with varying degree of success. Intra-operative and post-operative mitomycin-C (0.01-0.04%) with recurrence rate of 3-38% is another very commonly used modality [4,5].

Intra-operative Doxorubicin (0.02%), daunoribicin (0.02%), cyclosporine A (0.1%) eye-drops, thiotepa (0.05%) eye-drops and 5-fluoro-uracil (5%) are the other medical options shown to have promising results in recurrence prevention in various studies. Off-late, sub-conjunctival anti-VEGF Bevacizumab (1.25-2 mg) therapy has also been proposed for the aforesaid. All these agents are associated with risk of serious complications like scleral perforations, scleritis, scleral necrosis, and endophthalmitis (Figure 2).

surgery-current-research-mitomycin

Figure 2: Scleral perforation secondary to mitomycin-C application intraoperatively.

Role of beta-irradiation

The standard technique is a strontium (Sr90) brachytherapy with an epibulbar plaque which has central radioactive disc and non- active rim of 2 mm (Figure 3).

surgery-current-research-applicator

Figure 3: SR-90 Epibulbar applicator.

A total dose of 25 - 60 Gy is to be delivered in 1-6 fractions at a rate of 5-20 Gy/min. Most commonly, a dose of 30 Gy is delivered in 3 weekly fractions of 10 Gy with the first application being administered intra-operatively or at least within 48 hours after surgery.

Regimes of beta-irradiation advocated for recurrence prevention are

• Single application of beta-irradiation.

• Multiple applications over consecutive days immediately in postop period.

• Multiple applications over a 2-week period.

Cumbersome instrumentation and inconvenience of arranging its treatment account for the limited utility of this modality although the recurrence rates are comparable to post-operative mitomycin-C application [6].

Conjunctival auto-grafting and mitomycin-C are being used by all and the sundry, undermining the role of beta radiation. Though conjunctival auto grafting is considered the safest and most effective, it is time consuming. Time factor becomes very pertinent in developing countries where patient to ophthalmologist ratio is negatively skewed, incidence of pterygium is high and potentially blinding diseases account for the bulk of surgical time. Comparative data for beta radiation and mitomycin C are conflicting with Amano et al. suggesting superiority of mitomycin- C while Snibson et al. and Simsek et al. giving verdict in favour of beta irradiation [7-10].

Conclusion

Pterygium surgery has infallibly evolved over the years. Still the quest for an ideal recurrence free modality of pterygium management remains evasive and futile. This highlights the need to have a better understanding of the aetio-pathogenesis of pterygium as well as its recurrence. Also, treatment plan should be customized for each case rather than blindly following a single technique. Ironically, though ‘pterygium’ means a ‘small wing’, over the centuries its wings have expanded beyond our understanding and imagination. This triangular enigma can truly be called the ‘Bermuda triangle’ of ophthalmology as it continues to baffle us all. A concerted effort on our part is required to solve this mystery and Beta irradiation could prove to be the guiding light.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

  • International Conference on Bariatric surgery
    March 15-16, 2018, Barcelona, Spain

Article Usage

  • Total views: 330
  • [From(publication date):
    July-2017 - Dec 13, 2017]
  • Breakdown by view type
  • HTML page views : 300
  • PDF downloads : 30
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version